000			01877 a2200481 4500
005			20250516104643.0
264		0	_c20130405
008			201304s 0 0 eng d
022			_a1556-679X
024	7		_a10.1128/CVI.00386-12 _2doi
040			_aNLM _beng _cNLM
100	1		_aChioato, A
245	0	0	_aTreatment with the interleukin-17A-blocking antibody secukinumab does not interfere with the efficacy of influenza and meningococcal vaccinations in healthy subjects: results of an open-label, parallel-group, randomized single-center study. _h[electronic resource]
260			_bClinical and vaccine immunology : CVI _cOct 2012
300			_a1597-602 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
650	0	4	_aAdolescent
650	0	4	_aAdult
650	0	4	_aAntibodies, Bacterial _xblood
650	0	4	_aAntibodies, Monoclonal _xadverse effects
650	0	4	_aAntibodies, Monoclonal, Humanized
650	0	4	_aAntibodies, Viral _xblood
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aInfluenza Vaccines _ximmunology
650	0	4	_aInfluenza, Human _ximmunology
650	0	4	_aInterleukin-17 _xantagonists & inhibitors
650	0	4	_aMale
650	0	4	_aMeningococcal Infections _ximmunology
650	0	4	_aMeningococcal Vaccines _ximmunology
650	0	4	_aMiddle Aged
650	0	4	_aNeisseria meningitidis _ximmunology
650	0	4	_aOrthomyxoviridae _ximmunology
650	0	4	_aTh17 Cells _ximmunology
650	0	4	_aYoung Adult
700	1		_aNoseda, E
700	1		_aStevens, M
700	1		_aGaitatzis, N
700	1		_aKleinschmidt, A
700	1		_aPicaud, H
773	0		_tClinical and vaccine immunology : CVI _gvol. 19 _gno. 10 _gp. 1597-602
856	4	0	_uhttps://doi.org/10.1128/CVI.00386-12 _zAvailable from publisher's website
999			_c22009997 _d22009997